Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACITE trial of tacrolimus maintenance after first kidney transplant failure
2025-523386-26-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Oct 2026
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus in Kidney allograft failure (2 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Planned start Oct 2026; status: authorised.
02
Drugs
tacrolimus
03
Conditions
Kidney allograft failure
Beyond the preview
Go deeper on 2025-523386-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523386-26-00.